Benozol BR is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Dosage & Administration

Shake well before use.
Instill one drop in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.


Benozol BR contains Brinzolamide, a sulfonamide, and although administered topically is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of Benozol BR. Fatalities have occurred due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.

Brimonidine Tartrate also may potentiate syndromes associated with vascular insufficiency. Benozol BR should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud\'s phenomenon, orthostatic hypotension, or thromboangitis obliterans. anemia, and other blood dyscrasias. Brinzolamide and its metabolite are excreted predominantly by the kidney, Benozol BR is not recommended in renal impairment patients. The preservative in Benozol BR, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of Benozol BR but may be reinserted 15 minutes after.


Special Populations
Use in Pregnancy: Pregnancy Category C
Benozol BR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in Nursing Mothers:
It is not known whether Benozol BR are excreted in human milk following topical ocular administration. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Benozol BR , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in Pediatrics:
The individual component, Brinzolamide, has been studied in pediatric glaucoma patients 4 weeks to 5 years of age. The individual component, Brimonidine Tartrate, has been studied in pediatric patients 2 to 7 years old. Somnolence (50-83%) and decreased alertness was seen in patients 2 to 6 years old. Benozol BR is contraindicated in children under the age of 2 years
Use in Geriatrics:
No overall differences in safety or effectiveness have been observed between elderly and adult patients.

Product Details

Related Products

Alcadin (Alcaftadine 0.25%)

Alcaftadine 0.25%

Moxibac XG (Moxifloxacin 0.5%)

Brinzolamide 1% + Brimonidine Tartrate 0.2% Eye Drop

Ocustin (Bepotastine Besilatr 1.5%)

Brinzolamide 1% + Brimonidine Tartrate 0.2% Eye Drop

Optafenac (Nepafenac 0.1%)

Brinzolamide 1% + Brimonidine Tartrate 0.2% Eye Drop